10x Genomics Inc

Financials

Total assets 929.34 M1.02 B1.03 B965.14 M918.64 M1.04 B Total liabilities 190.27 M201.26 M223.24 M224.1 M208.5 M245.04 M Total equity 739.07 M817.57 M805.74 M741.04 M710.13 M796.33 M Total liabilities & shareholders' equities 929.34 M1.02 B1.03 B965.14 M918.64 M1.04 B Total debt —————— Net debt ——————

10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics.

TXG

Financials

10x Genomics Inc

Nouvelles

Canada stocks higher at close of trade; S&P/TSX Composite up 0.61%

Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?

Priceline, Carvana, DoorDash and more set to report earnings Wednesday

10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript

L’objectif de prix de l’action 10X Genomics relevé à 22$ contre 20$ par Canaccord Genuity

10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity

Applied Materials and Rivian among market cap stock movers on Friday

Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics

10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates

Le BPA de 10X Genomics a dépassé les attentes de 0,09$, le CA a surpassé les prévisions

10X Genomics face un test de résultats avec le lancement de sa nouvelle stratégie tarifaire

10X Genomics faces earnings test as new pricing strategy debuts